The IPO Buzz: French Biotech Abivax Preps for NASDAQ
Abivax S.A., a French biotech whose ulcerative colitis drug candidate is in Phase 3 clinical trials, aims to raise $250 million in its NASDAQ uplisting this week. Abivax (ABVX proposed) launched its U.S. public offering of 18.68 million American Depositary Shares (ADS) on Monday (Oct. 16, 2023) by disclosing terms and starting its roadshow. The […]
October 17, 2023 Read More